To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded GLP-1s—medications containing the same active ingredients as the blockbuster weight-loss drugs but sold at a much lower price.

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.